The **CGHS reimbursement cap** for oncology drugs is creating a major barrier to advanced cancer care in India. Consequently, the Association of Healthcare Providers (India) (AHPI) has formally addressed the health ministry regarding this growing crisis. Because the current policy limits reimbursement to 70% of the Maximum Retail Price (MRP), hospitals now face severe financial strain. This issue is particularly critical for patients who require life-saving immunotherapy drugs. These expensive, patented medications are essential for treating advanced stages of cancer.

Impact of the CGHS Reimbursement Cap on Hospitals

Hospitals find the current reimbursement pathways to be legally and operationally untenable. For instance, many hospitals procure patented drugs through bulk contracts with multinational pharmaceutical companies. These agreements explicitly prohibit the disclosure of negotiated prices to third parties. Therefore, submitting purchase invoices to the government could lead to breach of contract claims. Furthermore, drugmakers might initiate legal proceedings or halt supplies if confidentiality is compromised. Alternatively, asking patients to source their own medicines is medically dangerous. Because these drugs require strict cold chain maintenance, patients cannot easily verify the integrity of the medicine. Consequently, doctors are reluctant to administer drugs whose handling they cannot verify.

Risks to Patient Safety and Treatment Outcomes

The third option, relying on the direct CGHS supply system, has proven unreliable in practice. Patients frequently report delays and shortages within this system. Therefore, these disruptions lead to broken treatment schedules and suboptimal clinical outcomes. Since these patented drugs are very expensive, hospitals operate on thin margins of only 10-15%. Specifically, the 70% **CGHS reimbursement cap** forces hospitals to pay out-of-pocket for every infusion. This situation is unsustainable for private healthcare providers over the long term. Access to critical drugs like Keytruda, Imfinzi, and Enhertu remains at high risk for beneficiaries.

Frequently Asked Questions

Q1: Which specific drugs are most affected by the CGHS reimbursement policy?

The AHPI identified nine critical drugs, including Keytruda, Imfinzi, Enhertu, Imjudo, Zoladex LA, Adcetris, and Tagrisso. These patented medications are vital for treating advanced cancer but have high acquisition costs.

Q2: Why is the 70% reimbursement limit considered financially unsustainable for hospitals?

Hospitals typically operate on margins of 10-15% for these expensive drugs. Since the reimbursement is capped at 70% of the MRP, the shortfall often exceeds the hospital's profit margin, forcing them to incur a net loss for each dose administered.

Q3: What are the risks of patients sourcing their own immunotherapy drugs?

Immunotherapy drugs require strict temperature control or a "cold chain" during transport. If patients source them independently, hospitals cannot guarantee that the drugs were handled correctly, which may compromise patient safety and drug efficacy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Hospitals warn Central Government Health Scheme reimbursement cap may hurtcancer treatment - ETHealthworld


2. CGHS medical reimbursement limit hiked to Rs 10 lakh for these cases - The Economic Times


3. Strategic purchasing of oncology drugs to improve affordability and access to cancer care in India - PMC